Xenetic Biosciences Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jim Parslow
Chief executive officer
US$433.7k
Total compensation
| CEO salary percentage | 75.9% |
| CEO tenure | 7.6yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 5.3yrs |
Recent management updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$4m |
| Jun 30 2024 | n/a | n/a | -US$5m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$434k | US$329k | -US$4m |
| Sep 30 2023 | n/a | n/a | -US$4m |
| Jun 30 2023 | n/a | n/a | -US$4m |
| Mar 31 2023 | n/a | n/a | -US$6m |
| Dec 31 2022 | US$474k | US$329k | -US$7m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$7m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$521k | US$299k | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$359k | US$285k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$14m |
| Mar 31 2020 | n/a | n/a | -US$14m |
| Dec 31 2019 | US$388k | US$265k | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$19m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$288k | US$265k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$1m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | n/a | n/a | -US$3m |
| Dec 31 2017 | US$960k | US$199k | -US$4m |
Compensation vs Market: Jim's total compensation ($USD433.73K) is below average for companies of similar size in the US market ($USD647.72K).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Parslow (59 yo)
7.6yrs
Tenure
US$433,732
Compensation
Mr. James F. Parslow, also known as Jim, has been Chief Financial Officer at Xenetic Biosciences, Inc. since April 03, 2017 and serves as its Chief Operating Officer and Corporate Secretary and serves as i...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | 8.3yrs | US$563.49k | 0.027% $ 1.7k | |
| Independent Non Executive Director | less than a year | US$12.33k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$57.54k | 0% $ 0 | |
| Independent Director | 10.8yrs | US$57.54k | 0% $ 0 | |
| Non-Executive Director | less than a year | no data | 4.44% $ 276.6k | |
| Member of Scientific Advisory Board | 5.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Independent Director | 5.3yrs | US$57.54k | no data | |
| Independent Non-Executive Director | 5.2yrs | US$57.54k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data |
5.3yrs
Average Tenure
58yo
Average Age
Experienced Board: XBIO's board of directors are considered experienced (5.3 years average tenure).